WASHINGTON, October 15 — A national survey published in JAMA Psychiatry reveals that nearly half of adults using GLP-1 receptor agonists like Ozempic or Wegovy report reduced alcohol consumption, with heavier drinkers showing an even stronger response. The study, which gathered data from over 2,000 U.S. adults, found that 46% of participants who began using these medications reported drinking less alcohol. Among those identified as heavier drinkers prior to starting treatment, 54% said their alcohol intake decreased.
Researchers suggest the observed change may stem from the drugs’ influence on brain pathways tied to craving and reward, though the study design does not prove causation. GLP-1 receptor agonists are already widely prescribed for type 2 diabetes and weight management, acting by mimicking a natural hormone that regulates blood sugar and appetite.
How the medication works in the body and brain
GLP-1 receptor agonists activate receptors found not only in the pancreas but also in neurons throughout the brain, including regions involved in regulating food intake and reward signaling. In the hypothalamus, they stimulate neurons that promote feelings of fullness while suppressing those that drive hunger, helping to reduce caloric intake over time. Beyond metabolic effects, the drugs modulate dopamine-related pathways associated with reinforcement and motivation, which may explain their potential impact on behaviors like alcohol consumption.
This central nervous system activity distinguishes them from older diabetes treatments that work primarily in the periphery. The findings add to a growing body of evidence that GLP-1-based therapies may have broader applications beyond glycemic control, including potential roles in addressing substance use and compulsive behaviors.
However, the study’s authors stress the need for further investigation to understand the underlying mechanisms and determine whether these effects are consistent across different populations. As of 2026, the sitting U.S. administration under President Donald Trump, Vice President JD Vance, and Secretary of State Marco Rubio continues to support medical innovation through federal health agencies, though the study itself was conducted independently by researchers from multiple U.S. institutions.
Future research will need to explore long-term outcomes, optimal dosing for behavioral effects, and safety profiles when using these medications specifically to target alcohol-related health concerns. Consult your doctor for medical advice.
